BG108425A - Заместени пиразинони, пиридини и пиримидини като лиганди на кортикотропин освобождаващ фактор - Google Patents

Заместени пиразинони, пиридини и пиримидини като лиганди на кортикотропин освобождаващ фактор

Info

Publication number
BG108425A
BG108425A BG108425A BG10842503A BG108425A BG 108425 A BG108425 A BG 108425A BG 108425 A BG108425 A BG 108425A BG 10842503 A BG10842503 A BG 10842503A BG 108425 A BG108425 A BG 108425A
Authority
BG
Bulgaria
Prior art keywords
pyridines
pyrimidines
releasing factor
corticotropin releasing
substituted pyrazinones
Prior art date
Application number
BG108425A
Other languages
English (en)
Inventor
Argyrios Arvanitis
Paul Gilligan
Richard Hartz
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of BG108425A publication Critical patent/BG108425A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

Изобретението се отнася до нови заместени пиразинони, пиридини и пиримидини с формули. Те са особено полезни като рецепторни лиганди на кортикотропин освобождаващ фактор, а оттук и при лечението на редица неврологично свързани разстройства, например афективно разстройство, безпокойство и депресия. а
BG108425A 2001-05-14 2003-12-08 Заместени пиразинони, пиридини и пиримидини като лиганди на кортикотропин освобождаващ фактор BG108425A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29070601P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
BG108425A true BG108425A (bg) 2004-12-30

Family

ID=23117196

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108425A BG108425A (bg) 2001-05-14 2003-12-08 Заместени пиразинони, пиридини и пиримидини като лиганди на кортикотропин освобождаващ фактор

Country Status (23)

Country Link
US (2) US7205306B2 (bg)
EP (1) EP1392309B1 (bg)
JP (1) JP2004533447A (bg)
KR (1) KR20030094410A (bg)
CN (1) CN1527710A (bg)
BG (1) BG108425A (bg)
BR (1) BR0209575A (bg)
CA (1) CA2446980A1 (bg)
CZ (1) CZ20033053A3 (bg)
DE (1) DE60217669D1 (bg)
EE (1) EE200300546A (bg)
HK (1) HK1059220A1 (bg)
HU (1) HUP0304048A2 (bg)
IL (1) IL158669A0 (bg)
IS (1) IS7017A (bg)
MX (1) MXPA03010324A (bg)
NO (1) NO20035055D0 (bg)
PL (1) PL366577A1 (bg)
RU (1) RU2003135424A (bg)
SK (1) SK13752003A3 (bg)
WO (1) WO2002092090A1 (bg)
YU (1) YU90503A (bg)
ZA (1) ZA200308729B (bg)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012087A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Nuevas pirazinonas como antagonistas del receptor crf1.
AU2004295050A1 (en) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
TW200611695A (en) 2004-06-09 2006-04-16 Glaxo Group Ltd Pyrrolopyridine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
MX2008015648A (es) * 2006-06-21 2009-01-09 Du Pont Pirazinonas como inhibidores de proliferacion celular.
CN101679348A (zh) * 2007-01-10 2010-03-24 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
WO2008107398A2 (en) * 2007-03-02 2008-09-12 Basf Se Pyrazine compounds
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
NZ582586A (en) * 2007-07-21 2011-12-22 Albany Molecular Res Inc 5-pyridinone substituted indazoles
CN103342695B (zh) 2007-09-14 2015-04-22 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
JP5433582B2 (ja) 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
MX2010011792A (es) 2008-04-29 2010-11-25 Merck Patent Gmbh Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes.
CN102105149A (zh) * 2008-07-31 2011-06-22 百时美施贵宝公司 作为促肾上腺皮质激素释放因子受体活性调节剂的取代的氨基甲酸酯衍生物
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102786512A (zh) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200126026A (ko) 2014-01-21 2020-11-05 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN106061504B (zh) 2014-01-21 2019-09-06 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
DE4029648A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
CZ286892B6 (en) 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
EP0901476A4 (en) 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
AU3064397A (en) 1996-05-24 1997-12-09 Dow Chemical Company, The Process for preparing aliphatic ester compounds and alkanols
KR100548853B1 (ko) 1996-07-24 2006-02-02 브리스톨-마이어스 스퀴브 파마 컴파니 아졸로 트리아진 및 피리미딘
DE69710594T2 (de) * 1996-09-16 2002-08-29 Du Pont Pharmaceuticals Co., Wilmington Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
HUP0100179A3 (en) 1997-07-03 2002-12-28 Bristol Myers Squibb Pharma Co Imidazopyrimidine and imidazopyridine derivatives and pharmaceutical compositions thereof
AU8181098A (en) 1997-07-03 1999-01-25 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
WO1999011643A1 (en) 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
AU3213699A (en) 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
WO2000011003A1 (en) 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS

Also Published As

Publication number Publication date
KR20030094410A (ko) 2003-12-11
DE60217669D1 (de) 2007-03-08
CN1527710A (zh) 2004-09-08
HUP0304048A2 (hu) 2004-04-28
US20070155740A1 (en) 2007-07-05
MXPA03010324A (es) 2004-02-17
US7205306B2 (en) 2007-04-17
US7319100B2 (en) 2008-01-15
SK13752003A3 (en) 2004-11-03
BR0209575A (pt) 2004-04-20
ZA200308729B (en) 2005-02-10
IS7017A (is) 2003-11-07
EE200300546A (et) 2004-04-15
CZ20033053A3 (en) 2004-05-12
YU90503A (sh) 2006-03-03
NO20035055D0 (no) 2003-11-13
EP1392309A4 (en) 2006-01-18
PL366577A1 (en) 2005-02-07
EP1392309A1 (en) 2004-03-03
CA2446980A1 (en) 2002-11-21
US20030171380A1 (en) 2003-09-11
HK1059220A1 (en) 2004-06-25
JP2004533447A (ja) 2004-11-04
IL158669A0 (en) 2004-05-12
EP1392309B1 (en) 2007-01-17
RU2003135424A (ru) 2005-05-20
WO2002092090A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
BG108425A (bg) Заместени пиразинони, пиридини и пиримидини като лиганди на кортикотропин освобождаващ фактор
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
ATE221886T1 (de) Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
EA200702044A1 (ru) Имидазопиридазиновые соединения
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
MX2007015427A (es) Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres.
TW200503705A (en) 3-amino chroman and 2-amino tetralin derivatives
TW200602058A (en) Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
TW200510416A (en) P38 inhibitors and methods of use thereof
GB0209891D0 (en) Novel compounds
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
SG157231A1 (en) Substituted p-diaminobenzene derivatives
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
MXPA03010269A (es) Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
TW200509935A (en) Novel compounds
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
AU2002251788A1 (en) Novel compounds and uses thereof
MXPA04007026A (es) Pirimidinonas y pirimidintionas sustituidas.
TW200407316A (en) Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
MXPA05012087A (es) Nuevas pirazinonas como antagonistas del receptor crf1.